CS5001 + rituximab

CS5001 + rituximab is a combination regimen comprising CS5001 and rituximab, used as an investigational therapy in oncology. **CS5001** is a novel antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), designed to deliver a cytotoxic payload selectively to ROR1-expressing tumor cells. **Rituximab** is a chimeric monoclonal antibody that targets CD20 on B lymphocytes, inducing B-cell depletion through several immune-mediated mechanisms. The combination is being evaluated for synergistic activity in B-cell malignancies, leveraging CS5001’s targeted cytotoxicity and rituximab’s immune-mediated B-cell depletion for enhanced antitumor effects in lymphoid cancers.